Micrologix biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (633)	1/21/2000 1:32:00 PM
From: Sean Janzen	Read Replies (1) of 792

In addition, it looks like MBI will enter MBI-226 into phase I for acne in Q1/00. This market is thought to be $1 billion. Since MBI-226 has already passed Phase II for CVC there is some speculation that this drug could advance fairly rapidly to phase III for acne. The follow up by r2, on the Stockhouse board, is interesting. He feels that Yorktons projection fails to include MBI's entire drug pipeline. If this is the case then their $9. estimate looks conservative. stockhouse.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next